NCT04634396

Brief Summary

Caregivers of adults with dementia report higher stress, including anxiety and depressive symptoms, burden, and existential suffering, than caregivers of people with other chronic diseases.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable anxiety

Timeline
Completed

Started Jun 2019

Shorter than P25 for not_applicable anxiety

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 14, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 9, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 9, 2019

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

November 3, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

November 18, 2020

Completed
Last Updated

March 29, 2023

Status Verified

March 1, 2023

Enrollment Period

6 months

First QC Date

November 3, 2020

Last Update Submit

March 27, 2023

Conditions

Keywords

Alzheimer's diseaseDementiaCaregivingCaregiverAnxietyAcceptance and commitment therapyTelehealth

Outcome Measures

Primary Outcomes (1)

  • Anxiety symptoms measured by the Generalized Anxiety Disorder Scale (GAD-7)

    Anxiety will be measured using the GAD-7 which contains 7 items with total scores ranging from 0 to 21. Scores of 5, 10 and 15 are cut off scores for mild, moderate and severe anxiety respectively. An add-on item assessing the patient's global impression of symptom related impairment helps researchers understand the extent to which anxiety interferes in daily life. The GAD-7 has factorial validity for the diagnosis of general anxiety disorder and is sensitive to change

    through study completion, an average of 6 months

Secondary Outcomes (7)

  • Depressive symptoms measured by the Patient Health Questionnarie-9 (PHQ-9)

    through study completion, an average of 6 months

  • Caregiver burden measured by the Zarit Burden Interview (ZBI)

    through study completion, an average of 6 months

  • Physical, emotional and existential suffering to caregivers measured by the Experience of Suffering Scale (ESS)

    through study completion, an average of 6 months

  • Different strategies that caregivers use to cope measured with the Brief COPE

    through study completion, an average of 6 months

  • Caregivers psychological flexibility measured by the Acceptance and Action Questionnaire-II (AAQ-II)

    through study completion, an average of 6 months

  • +2 more secondary outcomes

Other Outcomes (2)

  • The feasibility of the TACTICs Intervention will be measured by accrual rate, attendance of sessions, and the retention in the study

    baseline and through study completion, an average of 6 months.

  • Caregivers acceptability of the TACTICs intervention

    through study completion, an average of 6 months

Study Arms (1)

Experimental TACTICs

OTHER

Telephone Acceptance and Commitment Therapy Intervention for Caregivers of adults with dementia (TACICS. Participants will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1 hour sessions by a trained interventionalist

Behavioral: ACT Acceptance and Commitment Therapy

Interventions

6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools

Experimental TACTICs

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Able to communicate in English
  • Able to provide informed consent
  • Listed as primary caregiver in the chart of a patient with Alzheimer's disease or related dementia (DARD)
  • Intends to continue caregiving form ADRD patient for at least 12 months or greater
  • Clinically elevated anxiety score (score of 10 or higher on GAD-7)

You may not qualify if:

  • Non-family member of the ADRD patient
  • Has ADRD or other serious mental illness diagnosis such as bipolar or schizophrenia as determined by ICD-10 code

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Regenstrief Institute, Inc.

Indianapolis, Indiana, 46202-4800, United States

Location

MeSH Terms

Conditions

Anxiety DisordersCaregiver BurdenAlzheimer DiseaseDementia

Condition Hierarchy (Ancestors)

Mental DisordersStress, PsychologicalBehavioral SymptomsBehaviorBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive Disorders

Study Officials

  • Shelley A. Johns, PhD

    Indiana University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Model Details: single arm proof of concept study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine

Study Record Dates

First Submitted

November 3, 2020

First Posted

November 18, 2020

Study Start

June 14, 2019

Primary Completion

December 9, 2019

Study Completion

December 9, 2019

Last Updated

March 29, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will share

In future manuscripts, the authors will list contact information and state that IPD is available upon request

Time Frame
Spring, 2021
Access Criteria
manuscripts

Locations